The White House Office Of American Innovation
has risen to the President's daring challenge:
“Supposing we hit the body with a tremendous, whether it’s ultraviolet or just very powerful light, and... supposing you brought the light inside the body, either through the skin or some other way. And then I see the disinfectant where it knocks it out in a minute -- is there a way we can do something like that, by injection inside, or almost a cleaning?"
with a brilliant new Strategic Disinfectant Initiative:
A trial to see whether two anti-malarial drugs could prevent Covid-19 has begun in Brighton and Oxford.
Chloroquine, hydroxychloroquine or a placebo will be given to more than 40,000 healthcare workers from Europe, Africa, Asia and South America.
All the participants are staff who are in contact with Covid-19 patients.
US President Donald Trump was criticised this week after he said he had been taking hydroxychloroquine, despite warnings it might be unsafe.
The first UK participants in the global trial are being enrolled on Thursday at the Brighton and Sussex University Hospitals and the John Radcliffe Hospital in Oxford.
They will be given either hydroxychloroquine or a placebo for three months. At sites in Asia, participants will be given chloroquine or a placebo.
These are the first of a planned 25 UK sites, with results expected by the end of the year.
The trial is open to anyone delivering direct care to coronavirus patients in the UK, as long as they have not been diagnosed with Covid-19.
It will test whether the drugs can prevent healthcare workers exposed to the virus from contracting it.
